Background: Atopic dermatitis (AD) is an inflammatory skin disorder with severe pruritus. Despite advancements in medicine, therapeutic treatments for AD are still limited. Eupatilin (5,7-dihydroxy-30,40,6-trimethoxyflavone) is one of the lipophilic flavonoids from Artemisia umbelliformis Lam. and Artemisia genipi Weber. Objective: Although it has been reported to act a role in improving inflammation, its action on AD is uncertain. In this study, we examined the role of eupatilin on AD-like skin lesions in NC/Nga mice. Methods: 2,4-dinitrochlorobenzene was repeatedly applied to the ear of NC/Nga mice to produce AD-like skin lesions. Eupatilin (1%, once a day for 5 consecutive days/week) was applied topically for four weeks for the evaluation of its therapeutic effects. Results: 1% eupatilin cream significantly reduced the clinical severity score of AD-like lesions, compared to the vehicle (p＜0.005). A histopathological analysis revealed that 1% eupatilin cream significantly decreased the mast cell infiltration as well as inflammatory cell infiltration, compared to the vehicle (p＜0.005). We showed that 1% eupatilin cream significantly reduced the expression of thymic stromal lymphopoietin, tumor necrosis factor-α, interleukin-4, and interleukin-19, but not interferon-γ, compared to the vehicle (p＜0.005). Conclusion: Considering the therapeutic reaction of eupatilin on AD-like lesions as in this study, the substance has a promising to be an adjuvant topical agent for the control of AD. (Ann Dermatol 29(1) 61∼68, 2017) 
INTRODUCTION
Atopic dermatitis (AD) is a common chronic inflammatory skin disease 1 . It is characterized by intense pruritus and relapsing eczema. Although the pathomechanisms of AD is not yet fully elucidated, studies on its pathogenesis have demonstrated that the disease is highly associated with the dysregulation of the immune system, in particular, T-helper 2 (Th2)-immune responses. Thymic stromal lymphopoietin (TSLP) as well as Th2 cell producing interleukin (IL)-4, IL-5 and IL-13 play main roles in the pathogenesis of AD. Recent progress has revealed that IL-19 is up-regulated by IL-4 related in the pathogenesis of AD 2 . Although Th2 cells are principal during the acute reaction of AD, Th1 cells producing interferon (IFN)-γ are highly expressed during the chronic AD phase 3, 4 . Until now, Local or systemic glucocorticosteroids as well as emollient is the main therapeutic modalities for control of AD 5, 6 . However, there have been controversies regarding their long-term use, because these steroids can produce side effects in AD patients 7 . Therefore, many researchers are trying to develop a more effective and safer topical agent for AD. Eupatilin (2-[3,4-dimethoxyphenyl]-5,7-dihydroxy-6-methoxychromen-4-one), is the main lipophilic flavonoid obtained from medicinal herbs of the genus Artemisia, such as Artemisia umbelliformis Lam. and Artemisia genipi Weber.
Eupatilin has cytoprotective and anti-apoptotic activities in gastric epithelial primary cells, and anti-proliferative activ- ities in cancer cells [8] [9] [10] . It has been also shown to act as an antioxidant by inhibiting reactive oxygen species and has anti-inflammatory activities such as the inhibition of 5-lipoxygenase 8 . Recently, some reports showed that eupatilin can inhibit the allergic effects of mast cells 11, 12 . Moreover, it inhibits the expression of the proinflammatory cytokines, including tumor necrosis factor (TNF)-α, IL-4, IL-6, and IL-18 through nuclear factor kappa B 11 . However, so far, no study has assessed the therapeutic effects and mechanisms of the topical application of eupatilin on AD murine models. AD animal model is spontaneously induced in the NC/Nga mouse 13 . A previous report showed that 2,4-dinitrochlorobenzene (DNCB), an electrophilic and cytotoxic benzene derivative, induces AD-like skin diseases in NC/Nga mice 14 . In this study, we aimed to examine the effect of topical eupatilin on AD-like cutaneous lesions in NC/Nga mouse. The result of topical eupatilin in AD-like NC/Nga mice was evaluated by counting the skin severity score and detecting histological changes of lesions and levels of mRNA expression of Th2 cytokines.
MATERIALS AND METHODS
All animal care was performed in accordance with the Guide for the Care and Use of Laboratory Animals (Washington, DC, USA) and was approved by the Animal Care and Use Committee of The Catholic University of Korea (2014-0172-01).
Animals and reagents
Four-week-old male NC/Nga mice were purchased from SLC Japan (Tokyo, Japan Induction of AD-like skin lesions in NC/Nga mice and topical application of eupatilin DNCB-induced AD-like skin lesions in NC/Nga mice were induced as described in the previous study 14 . To produce AD-like cutaneous lesions, DNCB was treated to the abdomens and ears of mice. For sensitization, 150 μl of 1% DNCB dissolved in 4:1 acetone:olive oil was epicutaneously applied to the abdomen once (day 7). One week after the sensitization (day 1), 20 μl of 0.4% DNCB was treated to the dorsal surface of each ear. The 0.4% DNCB was applied repeatedly to the ears every other day for four weeks, and then five times a week for a further four weeks along with other topical treatments 15 .
The experimental design is shown in Fig. 1 . Mice were divided into four groups (n=5 per group): (1) non-treated (NT) group, (2) DNCB+vehicle (VH), (3) DNCB+1% eupatilin cream (0.05 g per one ear), and (4) DNCB+0.03% tacrolimus ointment (0.05 g per one ear). The clinical severity score (erythema/hemorrhage, edema, excoriation/erosion and scaling/dryness) of AD was assessed. Each item was rated from 0 (none), 1 (mild), 2 (moderate), to 3 (severe). Ear thickness was measured once per week using dial calipers (Kori Seiki MFG, Tokyo, Japan). Two investigators in a blinded fashion independently performed the assessment 15 .
Histological examination
We evaluated the histological findings of the ear skin of each mouse whose sections were stained with hematoxylin and eosin (H&E). The ear skin of each mouse was prepared on the last day of the experiment (day 29), fixed with 4% formalin, and embedded in paraffin. Then, 5-μm-thick sections were cut and transferred onto slides. Deparaffinized skin sections were stained with H&E before they were examined at 100× magnification. We also investigated the number of mast cells in the skin with staining with toluidine blue (TB). To detect mast cell infiltration, the dorsal skin of each mouse was also prepared on the last day of the experiment (day 29) as described above. All deparaffinized skin sections were stained with TB. Two researchers independently conuted the number of mast cells in five randomly selected sites at 400× magnification.
Quantitative reverse transcription-polymerase chain reaction (QRT-PCR) measured in real time using the optical module 15 . Melt curves were used to determine product specificity. Results were normalized to the level of β-actin gene expression 15 . The analysis of relative gene expression data was conducted using the 2 −ΔΔCT method 15 . Experiments were examined two times.
Statistical analysis
All data were expressed as the mean±standard error of the mean. One-way or two-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was used for statistical analysis 15 . In comparisons of the three groups, we used the Kruskal-Wallis test . Differences were considered significant at p＜0.05. Statistical analyses were performed using Prism 5 (Graphad Software, San Diego, CA, USA).
RESULTS
Effect of topical 1% eupatilin cream on DNCB-induced AD-like skin lesions of NC/Nga mice
To investigate the effects of eupatilin on an AD murine model, inflammation was induced on the ears of Nc/Nga mice by DNCB applied three times a week. Topical appli- cations of DNCB on the ears of NC/Nga mice produce AD-like lesions including edematous erythema with scratching mark and dryness ( Fig. 2A) . The clinical severity grades of the DNCB+VH group gradually escalated after the first trial. On day 29 after the first trial, the clinical severity ratings dropped by 33% and 15% in the DNCB+1% eupatilin cream and DNCB+0.03% tacrolimus ointment group, individually, compared to the DNCB+VH group (Fig. 2B) . Treatment with 1% eupatilin significantly reduced DNCB-induced clinical severity score on day 29, compared to the DNCB+VH group (p＜0.05). Treatment with 1% eupatilin and 0.03% tacrolimus reduced DNCB-induced ear hyperplasia on day 29 by 26% and 23%, respectively, compared to the DNCB+VH group (Fig. 2C) .
Effect of topical 1% eupatilin cream on DNCB-induced epidermal hyperplasia and mast cell infiltration
In Fig. 3A , striking epidermal hyperplasia and inflammatory cell infiltration were shown in the dermis of NC/Nga mice, following DNCB (in the DNCB+VH group). In contrast, 1% eupatilin cream reduced the hyperkeratosis, epidermal or dermal thickening and inflammatory cells infiltration in the lesion. The epidermal thickness of 1% eupatilin group significantly reduced, compared to the DNCB+VH group (p＜0.05) (Fig. 3B) . Kim et al. 12 reported that eupatilin has a suppressive effect on the mediator release action of mast cells. We further examined the effect of eupatilin on the infiltrated mast cells. In Fig. 3C , application with DNCB induced infiltrated dermal mast cells. 1% eupatilin significantly reduced infiltrated mast cells, compared to the vehicle (p＜0.05). We didn't notice any significant difference in the number of mast cells between groups treated with 1% eupatilin and 0.03% tacrolimus.
Effect of topical 1% eupatilin cream on DNCB-induced mRNA expression of inflammatory cytokines
The expression of TNF-α, IL-4, IL-19, and IFN-γ was minimal in the NT group. However, their expression was significantly elevated following DNCB. The application of 1% eupatilin cream significantly reduced the expression of TSLP, TNF-α, IL-4, and IL-19 compared to the vehicle (p＜0.05; Fig. 4 ). The application of 1 % eupatilin cream couldn't significantly decrease the expression of IL-5 and IL-13 (data not shown). DNCB-treated IFN-γ expression of mRNA was also decreased by 1% eupatilin cream, but it was not significant compared to the vehicle.
DISCUSSION
Eupatilin takes in anti-inflammatory, anti-allergic and anti-cancer properties as well as mucosal protective effects 16 .
Here 22 showed that IL-4 upregulates IL-19 expression in keratinocytes. In addition, Myles et al. 23 reported that IL-19 is associated with inflammatory skin diseases including AD. They suggested that IL-19 is possibly a therapeutic target to alter the susceptibility to infection. Th1-type cytokines, such as IFN-γ, were shown to be produced in AD lesions in later stages 24, 25 . We showed that 1% eupatilin cream more effectively decreased the expression of Th2 cytokines (IL-4 and IL-19) than that of Th1 cytokines such as IFN-γ. However, in this study, 1% eupatilin cream couldn't decrease the level of IL-5 or IL-13 in the AD-like lesions. Overall, these findings suggest that the therapeutic effects of topical 1% eupatilin cream on AD-like skin lesions in NC/Nga mice are possibly mediated by proinflammatory and Th2-response modification.
In conclusion, these findings indicate that topical 1% eupatilin alleviates DNCB-treated AD-like skin lesions in NC/Nga mice. Therefore, we propose that eupatilin may be thought about a promising topical therapeutic candidate in the control of AD. Nonetheless, further studies are needed to show therapeutic mechanisms of 1% eupatilin cream on AD.
